Copilot says:

Below is a fact‑checked, citation‑supported summary of what is currently known (as of 28 Feb 2026) about polylaminin (polilaminina) as a treatment for spinal cord injury (SCI).

---

✅ Fact Check: Polylaminin for Spinal Cord Injury

What Polylaminin Is

Polylaminin is a polymerized form of laminin, an extracellular matrix protein important in neural development. It is produced by acid‑induced self‑assembly of purified human placental laminin and forms a 3‑D scaffold that promotes neuronal adhesion, axonal growth, and synaptic organization. [healio.com]

This polymer acts as a biological bridge when injected into the injured spinal cord, potentially guiding axonal regrowth in the damaged area. [polylaminin.org]

---

📊 Evidence Summary

1. Preclinical Studies (Animals)

Rodent studies

• Multiple studies show enhanced axonal regeneration and locomotor improvement when polylaminin is applied to rat spinal cord injuries. [healio.com]

Dog studies (chronic SCI)

• A longitudinal veterinary study in dogs with chronic SCI reported functional improvement and an acceptable safety profile.
  [healio.com]

Conclusion: Preclinical animal evidence is strong and consistent.

---

2. Human Data

A. 2024–2026 Pilot Studies (Exploratory, Not Peer‑Reviewed)

A 2024 medRxiv preprint and subsequent academic reports describe:

• 8 patients with acute, complete SCI treated within ~72 hours.
• 6 survived to 1‑month follow‑up, and all 6 recovered some voluntary motor control below the lesion, an unprecedented result given <15% spontaneous recovery in complete SCI. [medrxiv.org], [proceedings.science]

BUT, this data:

• Is from uncontrolled, open‑label, non‑randomized early-phase studies.
• Not peer‑reviewed.
• Too small (n=6 evaluable) to establish efficacy.

B. Compassionate/Legal-access cases (Brazil)

There are individual cases reported by Brazilian news and academic observers describing motor improvements, including:

• Ability to lift legs,
• Recover trunk control,
• Improved limb movement. [peq42.com]

These are encouraging but anecdotal, without controlled comparison.

---

3. Regulatory Status

Brazil (ANVISA)

• In January 2026, ANVISA authorized a Phase 1 clinical trial focusing on safety in 5 human volunteers with acute SCI.
  [healio.com]
• A previously registered Brazilian clinical trial (RBR‑9dfvgpm) outlines a randomized design with polylaminin injected within 72 hours of diagnosis.
  [ensaioscli...cos.gov.br]

No regulatory approval for clinical use exists yet—only research authorization.

---

⚠️ Limitations and Scientific Caution

Independent analyses emphasize:

• No completed, peer‑reviewed human clinical trials yet demonstrate effectiveness.
• Data remains preliminary, with small cohorts and no controls.
• Experts urge caution regarding media hype and note major methodological gaps (sample size, randomization, long‑term outcomes).
  [ibis.bio]

Even leading researchers describe polylaminin as a promising but unproven therapy pending completion of trials. [polylaminin.org]

---

🧠 What Is True and Supported

Well‑supported facts:

• Polylaminin is a polymerized, placenta-sourced laminin-based biomaterial.
• It shows strong regenerative effects in rodents and positive signals in dogs.
• Early human data reports motor recovery in several patients, but NOT validated by large clinical trials.
• Brazil has initiated a Phase 1 human safety trial approved by ANVISA.

What is NOT yet proven:

• That polylaminin can reliably restore walking or major motor function in humans.
• That it is safe and effective at scale.
• That it is superior to existing or other experimental therapies.

---

📌 Bottom Line

Polylaminin is one of the most promising experimental regenerative SCI therapies emerging globally, with compelling animal results and early human signals. However:

👉 It is NOT yet an established or clinically proven treatment.
👉 All human evidence is preliminary, small, and non‑peer‑reviewed.
👉 Only Phase 1 trials are currently authorized.